TheraRadar
Clinical-Stage Companies / MoonLake Immunotherapeutics

MoonLake Immunotherapeutics

Pre-Approval PRO BETA
10
Total Trials
7
Phase 3
2
Phase 2
5
Recruiting
139
Score

Pipeline by Phase

Phase 3
7
Phase 2
2
Phase 1
1

Therapeutic Focus

Hidradenitis Suppurativa Arthritis, Psoriatic Relative Bioequivalence

Clinical Trials (10)

NCT06641089 Phase 3 RECRUITING

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

Started: 10/15/2024

NCT06768671 Phase 3 RECRUITING

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

Started: 12/30/2024

NCT06641076 Phase 3 ACTIVE NOT RECRUITING

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

Started: 10/15/2024

NCT07223138 Phase 3 ENROLLING BY INVITATION

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

Started: 11/13/2025

NCT07007637 Phase 3 ENROLLING BY INVITATION

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

Started: 6/27/2025

NCT06411379 Phase 3 ACTIVE NOT RECRUITING

Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Started: 5/14/2024

NCT06411899 Phase 3 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Started: 5/15/2024

NCT05640245 Phase 2 COMPLETED

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Started: 12/13/2022

NCT05322473 Phase 2 COMPLETED

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

Started: 4/25/2022

NCT06994936 Phase 1 COMPLETED

An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector

Started: 6/5/2025

Drug Candidates

Sonelokimab Placebo Risankizumab Adalimumab Sonelokimab (M1095)
Activity Status: Active
Last Trial Started: 11/13/2025
Last Trial Ended: 11/1/2025
Trials (12 months): 3
Completed Trials: 3
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.